Hematologic Oncology

A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.

Key opinion leaders in lymphoma take a look at challenges in treating B-cell lymphoma and where they see the things moving in the future.

David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

The ability to reflect and boldly choose a professional identity should be discussed, encouraged, and nurtured in every individual.

Peter G. Miller, MD, PhD, discusses the characteristics and risks associated with clonal hematopoiesis and risk-stratification efforts for patients with cancer who are at risk of developing therapy-related secondary malignancies from clonal hematopoiesis.

Updated outcomes from the ongoing phase 1/2 GO40554 trial show that mosunetuzumab monotherapy demonstrated promising efficacy and a tolerable safety for elderly/unfit patients with previously untreated first-line diffuse large B-cell lymphoma.

Azra Raza, MD, discusses considerations for use of hypomethylating agents in older patients with high-risk myelodysplastic syndrome.

The panel of experts comment on the role of transplant in patients with myelodysplastic syndrome.

Mikkael A. Sekeres, MD, discusses his approach to treatment in patients with high-risk MDS incorporating efficacious clinical trial data.

Experts in the treatment of MDS discuss the clinical implications and treatment selection for patients with high-risk MDS.

Renowned experts in hematology-oncology provide insight into the practical implications of treating acute myeloid leukemia with the current standard-of-care regimen using venetoclax.

Key opinion leader in the management of acute myeloid leukemia, Harry Erba, MD PhD, builds a conversation on the use of venetoclax as a part of combination therapy in patients with IDH mutations.

Alexey V. Danilov, MD, discusses the safety and efficacy achieved with the novel combination comprised of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.

Ibrahim Aldoss, MD and James K. McCloskey, MD describe treatment modalities that can be utilized in treating a pediatric or AYA patient with relapsed / refractory ALL.

Insights on how to approach an acute lymphocytic leukemia patient who is MRD positive after induction therapy.

Patricia Lugar, MD, MS, shares treatment algorithm and supportive care recommendations for a 75-year-old man with systemic mastocytosis.

Peter G. Miller, MD, PhD, discusses the characteristics of clonal hematopoiesis.

The panel of experts in SM discuss the diagnosis and management of a 75-year-old man with systemic mastocytosis.

A comprehensive breakdown of the tolerability of frontline targeted therapies used to manage chronic lymphocytic leukemia and toxicity management.

After determining the parameters of high-risk CLL, key opinion leaders clarify optimal frontline management strategies.

Greg Nowakowski, MD, explains optimal approaches to bridging therapy before CAR T cell therapy in DLBCL.

A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.

Krina K. Patel, MD, MSc, discusses the use of CAR T-cell therapy in multiple myeloma, potential target antigens beyond BCMA, the rich research landscape, and the role of quadruplets and radiation therapy.

This article discusses the current treatment landscape and therapeutic strategies for Waldenström macroglobulinemia, the role of Bruton tyrosine kinase inhibitor therapies in WM, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

Duvelisib monotherapy demonstrated encouraging efficacy for patients with relapsed/refractory peripheral T-cell lymphoma.